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combined with the use of an inverse optimization method, 
can be used to generate IMPT plans. These plans can be used 
in future dosimetric comparisons with IMRT, the MR Linac and 
conventional IMPT. Finally, it shows the dosimetric feasibility 
of IMPT in a 1.5 T magnetic field.  
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Purpose/Objective: To compare the clinical benefit of robust 
optimized Intensity Modulated Proton Therapy (IMPT) with 
current photon radiotherapy (IMRT) and PTV-based IMPT for 
head and neck cancer (HNC) patients. The clinical benefit is 
quantified in terms of both Normal Tissue Complication 
Probability (NTCP) and target coverage in the case of setup 
and range errors. 
Materials and Methods: For 10 HNC patients, PTV-based IMRT 
(7 fields), robust optimized (minimax) and PTV-based IMPT 
(2, 3, 4, 5 and 7 fields) plans were tested on robustness, 
meaning that at least 98% of the CTVs had to receive ≥ 95% of 
the prescribed dose in 90% of the possible systematic setup 
and range error scenarios. Robust optimized plans differed 
from PTV-based plans in that they target the CTV and 
penalize possible error scenarios, instead of using the static 
isotropic CTV-PTV margin. Perturbed dose distributions of all 
plans were acquired by simulating in total 8060 setup (+/- 
2.5mm) and range error (+/-3%) combinations. Furthermore, 
NTCP models for xerostomia and dysphagia were used to 
estimate the clinical benefit of IMPT versus IMRT.  
Results: The robustness criterion was met in the IMRT and 
minimax IMPT plans in all error scenarios, but for PTV-based 
IMPT plans this was only the case in 4 out of 10 patients. The 
volumes receiving deficient dose were sometimes centrally 
situated in the CTV (Figure), indicating that expansion of the 
CTV-PTV margin would not solve the underdosage. Mean 
doses to the major salivary glands and swallowing related 
organs at risk (OAR) were generally lower with minimax than 
with PTV-based IMPT. Xerostomia and dysphagia NTCP values 
calculated for IMRT plans were reduced by 16.4% (95% CI; 
10.1-22.7%) and 9.9% (95% CI; 4.9-14.9%) with minimax IMPT 
in the 5 patients with the largest NTCP reductions. In the 
other 5 patients the average NTCP reduction was smaller 
(xerostomia: 4.7% (95% CI; 1.0-8.3%) ; dysphagia: 3.0% (95% 
CI; -0.2-6.2%). Increasing the number of fields did not 
contribute to plan robustness, but improved organ sparing. 
Conclusions: The clinical benefit in terms of NTCP of robust 
optimized (minimax) IMPT compared to IMRT is equal or even 
greater than that of PTV-based IMPT in head and neck 
patients. Furthermore, the target coverage of minimax IMPT 
plans in the presence of setup and range errors was 
comparable to that of current photon radiotherapy (IMRT) 
plans.
 
Figure. Dose distributions of IMRT (a,d), PTV-based IMPT (b,e) 
and minimax optimized IMPT plans (c,f) in nominal (a-c) and 
an error scenario (d-f) with a setup error of 
x=0.18;y=0;z=0.18cm and a range error of 3%. Both CTV70 
(blue lines) and CTV54.25 (black lines) are shown in all dose 
distributions.  
   
 
Proffered Papers: RTT 2: Modern treatment planning  
 
 
OC-0164   
Calibration and validation of kV-CBCT in room imaging for 
dose calculation and adaptive radiotherapy 
M. Soumokil- de Bree1, T.S. Rosario2, M.A. Palacios2 
1VUMC and INHOLLAND University, MBRT/ Radiotherapy, 
Haarlem, The Netherlands  
2VUMC, Radiotherapy, Amsterdam, The Netherlands  
 
Purpose/Objective: To investigate the accuracy of dose 
calculation on cone beam CT (CBCT) data sets after HU-RED 
calibration and validation in phantom studies and clinical 
patients. 
Materials and Methods: Calibration of HU-RED curves for kV-
CBCT were generated for three clinical protocols (H&N, 
thorax and pelvis) using a Gammex RMI phantom ® (Gammex 
RMI, Middleton, WI) with human tissue equivalent inserts and 
additional perspex blocks to account for patient scatter. Two 
calibration curves per clinical protocol were defined, one for 
the Varian Truebeam 2.0 and another for the OBI systems 
(Varian Medical Systems Inc., Palo Alto, USA). Differences in 
HU values with respect to the CT-calibration curve were 
evaluated for all the inserts. 
Four radiotherapy plans (breast, prostate, H&N and lung) 
were produced on an anthropomorphic phantom (Alderson) to 
evaluate dose differences on the kV-CBCT with the new 
calibration curves with respect to the CT based dose 
calculation. Dose calculation was performed in Eclipse TPS 
using an anisotropic analytic dose calculation algorithm (AAA, 
Varian Medical Systems Inc.). Dose differences were 
evaluated according to the D2%, D98% and Dmean metrics 
extracted from the DVHs of the plans and g- evaluation (2%, 
1mm) on the three planes at the isocenter for all plans. 
Clinical evaluation was performed on ten patients and dose 
differences were evaluated as in the phantom study. 
Results: HU values on the kV-CBCT calibration curves 
exhibited deviations with respect to the CT-calibration curve 
on the low- (lung) and high-density (bone) inserts. These 
deviations were found to be ca. 250 HU. Differences between 
the Truebeam 2.0 and OBI-system for HU-RED curve were 
ca.14 %. Radiotherapy plans calculated on the 
anthropomorphic phantom showed very good agreement with 
the CT-based calculated plans (Table 1, Figure 1).  
